TetraGenetics Announces Discovery of Functional Antibodies Against Nav1.8 at the Antibody Engineering & Therapeutics Virtual ConferenceZiad TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced today that they will be presenting news of the discovery of functional antibodies against Nav1.8 at the Antibody Engineering & Therapeutics Virtual Conference taking place Dec 14th – 16th.
TetraGenetics Appoints Alison Taunton-Rigby, Ellen Baron and Daniel Grau to its Board of DirectorsZiad TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced today the addition of three new board members: Alison Taunton-Rigby Ph.D., OBE, Ellen Baron Ph.D. and Daniel Grau M. Phil. Read more >>
Purdue Pharma taps TetraGenetics for ion channel-focused pain treatments in $273M discovery pactZiad Purdue Pharma’s newly formed clinical research subsidiary, Imbrium Therapeutics, has tapped TetraGenetics and its antibody discovery platform to help it develop new, non-opioid-based biologics for treating chronic pain. Read more >>
TetraGenetics Partners with LifeArc to Humanize New Drugs and Perform IND-Enabling StudiesZiadTetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases and pain, today announced a partnership with LifeArc®, the UK-based medical research charity. The collaboration brings together the drug discovery skills of TetraGenetics with the antibody humanization and development capabilities of LifeArc. Under the agreement LifeArc will humanize up to five new drug leads discovered by TetraGenetics and may support pre-IND (Investigational New Drug) studies for selected programs. TetraGenetics will manage the regulatory applications and the subsequent clinical trials for...
TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies Against KCa3.1ZiadTetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced a collaboration with ModiQuest Research, a Dutch biotechnology company with a suite of technologies for the discovery and optimization of monoclonal antibodies including those directed against difficult target antigens with low immunogenicity. Read more >>
JDRF Invests in TetraGenetics’ Innovative Approach to Type 1 Diabetes PreventionZiadA unique scientific approach to preventing, treating and, perhaps one day, curing type 1 diabetes is being coupled with JDRF’s equally innovative approach to funding such studies in a new partnership that might move the promise of a preventive therapy and improved treatment for the condition closer to reality. “This is a very targeted therapeutic approach to addressing type 1 diabetes,” says Dr. Ted Clark, the Chief Scientific Officer for TetraGenetics, a company that has been working for the past several...